Darzalex Faspro (daratumumab and hyaluronidase) significantly extended the time people with relapsed or refractory multiple myeloma live without disease worsening, when added to a combination of Pomalyst (pomalidomide) and dexamethasone, a Phase 3 clinical trial shows. Darzalex Faspro is a subcutaneous, or under-the-skin, formulation of Janssen‘s Darzalex (daratumumab), which is administered intravenously (into the vein). The randomized APOLLO trial (NCT03180736) included patients who had received at least one prior line of therapy, including the immunomodulatory…
You must be logged in to read/download the full post.
The post Darzalex Faspro Combo Shows Benefits for Relapsed, Refractory Myeloma in Phase 3 Trial appeared first on BioNewsFeeds.